NOK Inhibitors
NOK Inhibitors primarily encompass a range of chemical compounds that can influence the function or activity of the STYK1 kinase, commonly known as NOK. The primary method of action for these compounds stems from their ability to target a multitude of kinases, subsequently influencing the pathways in which STYK1 is involved. Dasatinib and Imatinib, for instance, are multikinase inhibitors. By targeting a broad spectrum of kinases, they have the potential to modulate the signaling processes associated with STYK1, even if not directly inhibiting the protein itself.
Similarly, compounds like Erlotinib and Lapatinib, which primarily target the EGFR family, can still impact STYK1 through their influence on downstream signaling pathways. On the other hand, broader kinase inhibitors like Sunitinib and Sorafenib can affect a myriad of pathways, including those in which STYK1 plays a role.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A multikinase inhibitor that can target several kinases, thereby potentially modulating STYK1-related pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Primarily a BCR-ABL inhibitor, but its multikinase activity can indirectly affect STYK1 functions. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Inhibits multiple receptor tyrosine kinases, which can affect pathways involving STYK1. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
An EGFR inhibitor which, through downstream effects, can potentially modulate STYK1's activity. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
By inhibiting EGFR and HER2/neu, it can affect downstream pathways and indirectly influence STYK1. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A Raf kinase and receptor tyrosine kinase inhibitor, which can affect STYK1-related signaling. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Targets VEGFR, EGFR, and RET, potentially affecting STYK1-related pathways. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Inhibits BCR-ABL and other kinases, which can modulate pathways associated with STYK1. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
A BCR-ABL inhibitor with broad spectrum kinase inhibition, possibly influencing STYK1. | ||||||
Canertinib | 267243-28-7 | sc-207397 | 10 mg | $260.00 | 3 | |
EGFR family inhibitor, which by targeting EGFR can affect pathways related to STYK1. | ||||||